Savara (SVRA) Reports Complete Enrollment in Molgradex OPTIMA Clinical Study for Treatment of NTM

October 31, 2018 8:06 AM EDT Send to a Friend
Savara Inc. (NASDAQ: SVRA) today announced completion of the target enrollment of 30 patients in OPTIMA, a Phase 2a clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login